|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Division of Allergy/Immunology, Department of
Pediatrics, North Shore University Hospital, New York University School
of Medicine, Manhasset, NY.
Indinavir (IDV) is a potent and selective human immunodeficiency
virus type 1 (HIV-1) protease inhibitor (PI) widely used in
antiretroviral therapy for suppression of HIV, but its effects on the
immune system are relatively unknown. Recently, it has been reported
that PIs inhibit lymphocyte apoptosis. In the present study we have
investigated the effects of ex vivo addition of IDV on lymphocyte
activation and apoptosis in cells from HIV-infected children (n = 18)
and from healthy uninfected individuals (controls, n = 5) as well as
in Jurkat and PM1 T-cell lines. Pretreatment of control peripheral
blood mononuclear cell (PBMC) cultures with IDV resulted in a
dose-dependent inhibition of lymphoproliferative responses to different
activation stimuli. Additionally, this treatment led to cell-cycle
arrest in G0/G1 phase in anti-CD3 monoclonal antibody-stimulated PBMC
cultures in controls and in 15 of 18 HIV-infected children.
Spontaneous- or activation-induced apoptosis of PBMCs from HIV-infected
or uninfected individuals or of Fas-induced apoptosis in Jurkat and PM1
T cell lines were not inhibited by IDV. Moreover, IDV did not inhibit
activation of caspases-1, -3, -4, -5, -9, and -8 in lysates of Jurkat T
cells undergoing Fas-induced apoptosis. The findings indicate that IDV interferes with cell-cycle progression in primary cells but does not
directly affect apoptosis. It is concluded that IDV may prolong cell
survival indirectly by inhibiting their entry into cell cycle. In individuals on PI therapy, PI-mediated effects could potentially modulate immunologic responses independently of antiviral activity against HIV.
(Blood. 2001;98:383-389) Immunodeficiency is a hallmark of human
immunodeficiency virus type 1 (HIV-1) disease and is characterized by a
progressive decrease in CD4 T cells. The introduction of combination
therapies (eg, with drugs targeting the viral-specific enzymes reverse
transcriptase and protease1-3) have had a dramatic effect
in slowing disease progression. In the majority of patients, drug
regimens containing HIV-1 protease inhibitors (PIs) and reverse
transcriptase inhibitors (RTIs) are effective in reducing plasma viral
burden, with concomitant increase in CD4 lymphocyte
counts.4,5 When therapy fails, the virologic rebound is
associated with a decline in CD4 T cells. Curiously, in a subset of
patients, the immunologic benefit persists despite virologic
failure.6,7 The mechanism of this "discordant" response is not clearly understood, and the observed effects have been
ascribed to virologic factors as well as to direct effects of the PIs
on the immune system, distinct from their antiviral effects.
Mechanisms of CD4 T-cell loss in HIV disease have been under debate for
several years. Loss of CD4 T cells by apoptosis has been put forth as
one mechanism for the immune deficiency in HIV infection. Increased
lymphocyte apoptosis is recognized as a feature of HIV infection and
has been attributed to direct and indirect effects of HIV on the immune
system.8,9 Therapy-induced decrease in plasma HIV RNA has,
in fact, been shown to result in reduction in lymphocyte
apoptosis.10,11 The antiviral effect of PI drugs is
mediated by the inhibition of the HIV protease, the enzyme that is
required for the processing of HIV polypeptides into smaller peptides
and maturation of viral particles.12-14 It has been argued that the similarity between HIV protease (an aspartyl protease) and the
cellular caspases (cysteine proteases) involved in apoptosis could
result in PI-mediated anticaspase activity.13-16 Some
recent studies with the PI Ritonavir have implicated a direct
antiapoptotic effect of the drug on T cells17-19 as a
possible mechanism for CD4 T-cell increase following therapy. However,
in another study, the in vitro addition of the PI Indinavir (IDV) to
cells of HIV-infected patients did not result in antiapoptotic
effects.20 The mechanism by which PI therapy results in
immunologic benefit independently of its antiviral effects thus remains unclear.
A characteristic feature of PIs is their ability to modulate
proteosomes21,22 that are involved in a variety of
cellular functions and constitute an important component of the
biological system. It has been shown that this effect of PIs on
proteosomes impairs antigen presentation and processing by
antigen-presenting cells.21 In addition, PIs have also
been shown to influence lymphocyte proliferation20,23; the
reported effects, however, have been contradictory, presumably because
the experimental systems have been different as have the doses of drugs
used, which have varied widely in these studies.
In the present study we have tested the hypothesis that PIs mediate
immunomodulatory effects that can influence host immunity in a manner
distinct from the benefits attributable to control of viral
replication. Here we have examined the effect of therapeutic concentrations of IDV on lymphocyte activation and on spontaneous and
activation-induced lymphocyte apoptosis in peripheral blood mononuclear
cell (PBMC) cultures of healthy volunteers and HIV-infected patients
and in T cell lines.
Donors
Isolation of cells
Cell lines and other reagents Two different T-cell lines, Jurkat (clone E6-1; ATCC, American Type Culture Collection, Manassas, VA) and PM124 (AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) were maintained and cultured in RPMI 1640, 10% fetal bovine serum, 2 mM L-glutamine, and antibiotics penicillin and streptomycin. Antihuman Fas (CD95) monoclonal antibody (mAb) CH11 and fluorogenic substrates Ac-YVAD-AFC, Ac-DEVD-AFC, Ac-LEHD-AFC, and Ac-IETD-AFC of caspase-1; caspase-3; caspases-4, -5, and -9; and caspase-8, respectively, and their specific inhibitors (Ac-YVAD-CHO, Z-DEVD-FMK, Z-LEHD-FMK, and Z-IETD-FMK, respectively) were purchased from Kamiya Biomedical Company (Seattle, WA). Purified mouse antihuman CD3 mAb was purchased from BD Pharmingen (San Diego, CA). A gift of IDV sulfate powder was generously given by Merck Research Laboratories (Rahway, NJ). RNAse, phytohemagglutinin (PHA), concanavalin A (Con A), phorbol 12-myristate 13-acetate (PMA), and Ionomycin were purchased from Sigma (St Louis, MO), and propidium iodide was obtained from Molecular Probes (Eugene, OR).Culture conditions and measurement of lymphocyte apoptosis and cell-cycle profiles Test PBMCs were cultured for 3 days with anti-CD3 mAb (0.5 µg/mL) or with control isotype-matched antibody to study spontaneous- and activation-induced lymphocyte apoptosis. To study the effect of IDV, the drug was added ex vivo to PBMC cultures for 18 hours in 24-well culture plates (Becton Dickinson Labware, Franklin Lakes, NJ). Different concentrations of IDV were prepared from IDV powder dissolved in dimethyl sulfoxide (DMSO) and added to the cultures at a final dilution of 1 µL/mL. Thereafter, the cells were cultured with anti-CD3 mAb (0.5 µg/mL) or with control isotype-matched antibody for an additional 48 hours. At termination of cultures, cells were harvested by centrifugation, washed, and fixed in 70% ethanol for 1 hour and incubated with propidium iodide (50 µg/mL) and RNAse (100 µg/ml). Samples were kept in the dark at room temperature for 30 minutes and stored at 4°C until analyzed for cell-cycle profile and apoptosis. In healthy volunteers, for the study of IDV effect on lymphocyte apoptosis, additional experiments were performed to simulate the state of in vivo lymphocyte activation, which is a characteristic feature of the HIV-infected state. PBMCs were first activated with PHA (2 µg/mL) for 4 days, washed, and then treated as described above with different concentrations of IDV for 18 hours, followed by activation with anti-CD3 mAb for 48 hours.Apoptosis in Jurkat and PM1 T cells was induced through Fas death pathway by culturing the cells with anti-Fas mAb CH11 (100 ng/mL) in the presence of different concentrations of IDV for 2, 6, and 18 hours. In other experiments, Jurkat and PM1 T cells were precultured with different concentrations of IDV for 18 hours followed by treatment with CH11 for 6 and 18 hours. To investigate the effect of IDV on the cell cycle, Jurkat and PM1 T cells were cultured with different concentrations of IDV over periods of 24, 48, and 72 hours and stained with propidium iodide. Lymphocyte apoptosis was investigated as described in propidium iodide-stained cells using the Coulter Epics Elite ESP (Coulter, Hialeah, FL) instrument after careful gating for lymphocytes.25 For cell-cycle studies, DNA content was determined by using listmode files with the multicycle flow cytometry software (Phoenix Flow System, San Diego, CA). In healthy volunteers, results of cycling cells (in S + G2/M phase) or of cells undergoing apoptosis were expressed as a percentage of total cells for that culture condition. In patients, cycling cells and apoptotic cells in IDV-treated cultures are expressed as a percentage of cycling cells or apoptotic cells in cultures without IDV (ie, cells precultured with 1 µL/mL DMSO). Lymphoproliferation studies PBMCs from healthy human volunteers were precultured in medium alone or with different concentrations of IDV for 18 hours in 96-well plates (Becton Dickinson Labware), followed by the addition of stimuli in triplicate [viz, anti-CD3 mAb (0.5 µg/mL), PHA (2 µg/mL), Con A (2 µg/mL), PMA (10 ng/mL) plus Ionomycin (1 µM)], isotype-matched antibodies, or DMSO (control) for an additional 48 hours. Cultures were pulsed with [14C]-thymidine (1 µCi/well) for the last 18 hours, and uptake of [14C]-thymidine in cells was quantitated by scintillation counting.26 Lymphoproliferative responses of IDV-treated cultures are expressed as the percentage of [14C]-thymidine incorporated in cultures without IDV treatment.Study of caspase activity Cell lysates from CH11-treated Jurkat CD4 T cells was used to quantitate activity of caspase-1, -3, -4, -5, -9, and -8. In brief, 1 × 106 Jurkat CD4 T cells/mL were cultured with 100 ng/mL anti-Fas antibody CH11 for 3 hours. Cells were washed once with ice-cold Hanks balanced salt solution, followed by suspension in cell lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1 mg/mL leupeptin, and 20 mg/mL aprotinin] for 20 minutes. Cells were incubated on ice for 20 minutes and then disrupted by passing through a 20-gauge needle for 10 times. Cell extracts were clarified by centrifugation at 16 000g for 15 minutes at 4°C. To study the effect of IDV on caspase activity, cell extracts were incubated with different concentrations of IDV (12.5 µM to 100 µM) or with specific caspase inhibitors (Ac-YVAD-CHO, Z-DEVD-FMK, Z-LEHD-FMK, and Z-IETD-FMK) followed by addition of caspase-specific fluorogenic substrates (Ac-YVAD-AFC, Ac-DEVD-AFC, Ac-LEHD-AFC, and Ac-IETD-AFC) for caspase-1; caspase-3; caspases-4, -5, and -9; and caspase-8, respectively. Activity of each caspase was estimated as a release of 7-amino-4-trifluoromethyl coumarin (AFC) from the caspase-specific substrate and measured by dual scanning microplate spectrofluorometer (SPECTRAmax Gemini XS; Molecular Devices, Sunnyvale, CA). Kinetics of individual reactions were monitored for 2 hours at 37°C in the microplate spectrofluorometer.Statistical analysis SigmaStat 2.0 statistical software (Jandel Scientific Software, San Rafel, CA) was used for all statistical analysis.
IDV blocks lymphocyte cell cycle in G0/G1 phase in cells from healthy volunteers and HIV-infected children PBMCs from healthy volunteers and from HIV-infected children were incubated in the absence or presence of different concentrations of IDV for 18 hours followed by stimulation with anti-CD3 or control antibodies for an additional 48 hours. The effect of IDV on anti-CD3 mAb-induced cell-cycle progression in healthy volunteers is shown in Figure 1A. Preincubation of PBMCs with IDV blocked anti-CD3-induced cell-cycle progression in a dose-dependent manner. IDV was found to block cells in the G0/G1 phase, prior to their entry into synthesis phase (S). At the lowest concentration of IDV (5 µM), 36.2% ± 3.5% cells were in cell cycle compared with 47.2 ± 1.2 cycling cells in PBMCs cultured with anti-CD3 mAb without prior exposure to IDV (P < .05). At the highest concentration of IDV (50 µM), only 15% ± 1.3% cells were in cycling phase. The effect of IDV on anti-CD3-induced cell-cycle progression in PBMCs of HIV-infected children is shown in Figure 1B. Pretreatment of PBMCs with IDV was found to inhibit anti-CD3-induced cell entry into S phase in a dose-dependent manner in 15 of 18 HIV-infected children. The ex vivo blocking effect of IDV on anti-CD3-induced cell cycling was noted to occur in patients regardless of whether they were receiving PI therapy or not. Addition of IDV at the same time as anti-CD3 mAb did not inhibit cell-cycle progression. Viability of cells was equivalent in cultures with or without IDV pretreatment.
IDV impairs lymphoproliferative responses Pretreatment of PBMC cultures of healthy volunteers with IDV (0-50 µM) for 18 hours, followed by stimulation with anti-CD3 mAb (0.5 µg/mL) for 48 hours resulted in dose-dependent reduction of lymphoproliferative responses (Figure 2). This antiproliferative effect of IDV was also noted for cultures stimulated with PHA, PMA plus Ionomycin, or Con A. A similar pattern of dose-dependent inhibition was noted in cultures of unstimulated cells, with more than 50% inhibition of [14C]-thymidine uptake at a 5 to 10 µM dose range of IDV. At 18 hours after preincubation of PBMCs with IDV, no significant difference in [14C]-thymidine uptake and cell viability was noted between cells cultured with and without different concentrations of IDV (data not shown).
Spontaneous and anti-CD3-induced lymphocyte apoptosis in HIV-infected children Spontaneous lymphocyte apoptosis was investigated in 3-day PBMC cultures of HIV-infected children. As shown in Figure 3, spontaneous lymphocyte apoptosis was not significantly different in HIV-infected children who were on PI drug regimens (range, 4.4% to 34%; median, 10%) from those not on PI-containing drug regimens (range, 4.3% to 33%; median, 20%). Activation-induced lymphocyte apoptosis following anti-CD3 stimulation, however, was significantly increased over spontaneous apoptosis only in children on non-PI therapies, whereas the percentage of lymphocyte apoptosis remained unaffected following anti-CD3 activation in children who were on PI regimens. Anti-CD3-induced lymphocyte apoptosis was also significantly higher in children on non-PI drug regimens (range, 7.6% to 47%; median, 25.1%) as compared with those on PI-containing drug regimens (range, 6.5% to 34%; median, 12.2%; P < .05).
IDV does not inhibit lymphocyte apoptosis Preincubation of PBMCs from HIV-infected children with IDV (5-50 µM) did not influence spontaneous or anti-CD3-induced apoptosis (Figure 4A); this response was not different between patients receiving PI- or non-PI-containing antiretroviral therapies (data not shown).
In PBMCs of healthy individuals, the above protocol of 18 hours' preincubation with IDV followed by anti-CD3 activation yielded very few cells undergoing apoptosis. These studies were extended to examine the effect of IDV in apoptosis of PBMC cultures following prior activation with PHA (Figure 4B). PBMCs from healthy volunteers were cultured with PHA (2 µg/mL) for 4 days followed by incubation with different concentrations of IDV for 18 hours. These activated cells were cultured with anti-CD3 or control mAb (0.5 µg/mL) for an additional 48 hours to study activation-induced apoptosis. No significant difference in apoptosis was noted in PBMC cultures that were treated or not treated with different concentrations of IDV, whereas anti-CD3-induced apoptosis was significantly blocked by Ac-DEVD-CHO, a known inhibitor of caspases. IDV does not influence cell cycle or apoptosis of Jurkat and PM1 T-cell lines IDV at concentrations of 5 to 50 µM did not influence the cell-cycle profile of Jurkat (Figure 5A) or PM1 (Figure 5B) T-cell lines over incubation periods of 24, 48, or 72 hours. Fas-induced apoptosis was not inhibited in cells precultured with different concentrations of IDV or in cultures simultaneously incubated with different concentrations of IDV and anti-Fas antibody CH11, either in Jurkat (Figure 5C) or PM1 T cells (Figure 5D) over a period of 2 to 18 hours.
IDV does not inhibit caspase activity The activity of caspases-1, -3, -4, -5, -9, and -8 over 120 minutes in lysates of CH11 mAb-treated Jurkat T cells as demonstrated by release of AFC from caspase-specific fluorogenic substrates is illustrated in Figure 6. IDV at concentrations of 12.5 to 100 µM did not inhibit the activity of any of the caspases, whereas addition of caspase-specific inhibitors resulted in the expected inhibition of caspase activity.
Combination therapies with HIV PIs have had a dramatic effect on the survival of HIV-infected patients.27,28 An intriguing observation is that, in a subset of patients, the increase in CD4 T cells and the decrease in activation status of T cells can be sustained, despite virologic relapse after development of drug resistance.6,7,29 It has recently been suggested that PIs can directly inhibit lymphocyte apoptosis and that this effect may contribute to an immunologic benefit independently of an antiviral effect.17-19 In the present study we demonstrate that the effects of the PI, IDV, are broad ranging and that at therapeutic concentrations IDV can inhibit entry of cells into cell cycle. The drug was found to inhibit cell proliferation but had no direct antiapoptotic activity nor did it inhibit cellular caspases involved in apoptosis. These findings, and the known effects of HIV proteases and HIV PIs on cellular proteases and proteasomes,21,22,30-32 implicate PIs in potentially modulating a wide range of immunologic responses and provide insight into a mechanism for promoting cell survival, without directly influencing cell death. A novel finding in this study was that IDV blocks cells from entering into cell cycle. This effect was reflected in the inhibition of cell proliferation following activation stimuli. In fact, IDV was found to inhibit 14C-thymidine uptake in cells activated through 3 different pathways: direct T-cell receptor cross-linking using anti-CD3 mAbs, indirect T-cell activation induced by mitogens such as PHA and ConA, as well as activation induced by pharmacologic means using PMA plus Ionomycin. These findings are in agreement with the previously reported antiproliferative effects of IDV reported for myeloblastic and promyelocytic leukemia cell lines.23 The broad-based antiproliferative effect favors the likelihood of inhibition of proteasomal activity,21,22 or modulation of cytokine production.33-36 Proteasomes are the main proteolytic complexes operating in the cytosol and nucleus and are involved in many biological and degradative processes.37,38 The PI, Ritonavir, has been shown to block the chymotrypsin-like activity of murine 20S proteasome.21,22 Proteasomes control the cell cycle by proteolytic degradation of several cell-cycle regulatory proteins such as cyclins, cyclin-dependent kinases, and their inhibitors.37,38 Additionally, PIs have been reported to influence cytokines that regulate lymphocyte proliferation.33-36,39,40 It has been shown that the serum levels of interleukin 16 (IL-16) are increased in patients on IDV-containing drug regimens.35,36 IL-16 is known to inhibit anti-CD3-induced lymphocyte activation and lymphoproliferation.39,40 These observations, together with our findings, suggest that IDV may be blocking cell-cycle progression in lymphocytes, possibly by enhancing the levels of IL-16 production in association with the blocking of proteasomal activity. Recent clinical investigations, including our own studies and those of
several other groups, have shown that following potent antiretroviral
therapy a decrease in virus load is accompanied by an increase in CD4
T-cell counts and decreased T-cell apoptosis.10,11,41-43 Accelerated lymphocyte apoptosis is a well-known feature of HIV disease.8,9,44,45 The increased apoptosis involving CD4 and CD8 T cells in HIV infection has been explained on the basis of
host and viral factors.9,44 Host factors implicated
include imbalance in cytokine production and immune activation
following HIV infection that results in increased expression of death
receptors and ligands.45 Viral factors include viral
proteins (gp120, vpr, tat, nef, and protease), all of which have been
shown to influence lymphocyte apoptosis in vitro.46-50
Thus, the decrease in lymphocyte apoptosis in patients on
antiretroviral therapy has been attributed to the rescue of cells from
the direct and indirect effects of HIV. Additionally, the PIs
themselves have been ascribed to have antiapoptotic properties.
Although the activity of PIs is aimed at viral proteases, it has been
hypothesized that they can influence host cellular proteases (viz,
caspases) because of the similarity shared by these proteases at their
active sites. Ritonavir has been reported to inhibit apoptosis in PBMCs
cultured from HIV The differences in our findings from the reported inhibition of lymphocyte apoptosis and of caspase activity by PIs17-19 can be explained on the basis of the difference in experimental systems and in data interpretation. A major difference is that we used short-term exposure of lymphocytes to IDV (18 hours), whereas others17-19 have used longer culture periods (3-15 days) with Ritonavir prior to lymphocyte activation. Thus, in cells cultured for longer duration with a PI, fewer cells would be cycling because PIs block their entry into cell cycle. It has been shown that cells that have undergone multiple rounds of cell division are more susceptible to apoptosis51 (Chavan et al, unpublished observations, 2000). Thus, cells cultured for prolonged periods with a PI would be expected to exhibit apparently reduced apoptosis as compared with cells cultured in the absence of the PI. These cells would also be expected to show less caspase activity, as reported by Sloand et al17,18 and Weichold et al19 even without a direct effect of the PI on caspases, as shown in our study. The cell-cycle inhibitory effect of PIs could also be a factor responsible for the smaller increase of apoptosis following anti-CD3 stimulation in cells of patients on PI therapy as compared with patients not on PI therapy. Collectively, these studies indicate that IDV may not have a direct effect on apoptosis but may prolong cell survival by inhibition of cell-cycle progression. The difference in the molecular structure of IDV and Ritonavir is a less likely explanation for differential effects on lymphocyte apoptosis. In agreement with this contention we have found that another PI, Nelfinavir, has effects similar to IDV on cell-cycle progression without direct antiapoptotic activity (Chavan et al, unpublished observations, 2000). The inhibition of cell-cycle progression and antiproliferative property of IDV could affect the host/virus relationship in various ways, as well as modulate immune responses in general. Potential adverse effects of IDV include inhibition of clonal expansion of the cells of the immune system.52 PIs are known to have unexplained toxicities such as abnormal fat distribution and lipodystrophy, insulin-resistant diabetes, and hypercholesteremia.53-56 Inhibition of cell-cycle progression by IDV may be a potential factor contributing to the increased differentiation of lipid-producing adipose tissues,53,54 as cell-cycle blocking is essential for differentiation of adipose cells. Interestingly, the effect of IDV on cell cycle was seen only in primary PBMC cultures, and IDV was unable to block continuously cycling cells such as Jurkat and PM1. Thus, inhibition of immune activation may be restricted to newly recruited cells. This property of PIs may in fact be beneficial to the host in terms of host/virus interaction; a decrease in activation of the immune system may prevent the spread of the virus and T-cell-mediated immunopathogenesis in HIV infection. It has been well documented that HIV replication is supported mainly in cycling cells.57,58 HIV-specific proteins such as vpr block the cells in G2 phase that the virus uses to its advantage to increase the synthesis of viral proteins, and thereby increases its replication.59 Blocking of the cells in G0/G1 phase by PIs could result in reduced viral production of wild-type as well as drug-resistant mutant virus strains, thereby contributing to persistent benefit despite development of viral resistance mutations observed in different clinical cohorts.31 Additionally, as reported by Ikezoe et al,23 this property might be useful for treatment of patients with acute promyelocytic leukemia with PIs. Elucidation of mechanisms by which PIs block cell-cycle progression and exert antiproliferative activity will provide insight into the full effect of PI therapy on the immunopathogenesis of HIV disease and open new vistas for disease targets for this class of agents.
Submitted January 3, 2001; accepted March 16, 2001.
Supported by grants AI28281 and DA05161 from the National Institutes of Health, Bethesda, MD.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Savita Pahwa, Division of Allergy/Immunology, North Shore University Hospital, NYU School of Medicine, 350 Community Dr, Research Bldg #303, Manhasset, NY 11030; e-mail: spahwa{at}nshs.edu.
1. Gazzard B. The picture of future therapy. Int J Clin Pract Suppl. 1999;103:45-48[Medline] [Order article via Infotrieve].
2.
Clumeck N.
Choosing the best initial therapy for HIV-1 infection [editorial; comment].
N Engl J Med.
1999;341:1925-1926 3. Kiso Y. Protease inhibitors [editorial]. Biopolymers. 1999;51:1[CrossRef][Medline] [Order article via Infotrieve]. 4. Mitsuyasu R. HIV protease inhibitors: immunological insights. AIDS. 1999;13(suppl 1):S19-S27. 5. Pradier C, Pesce A, Carrieri P, et al. Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy. Clin Ther. 1999;21:1313-1320[CrossRef][Medline] [Order article via Infotrieve]. 6. Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423-1430[CrossRef][Medline] [Order article via Infotrieve]. 7. Belec L, Piketty C, Si-Mohamed A, et al. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis. 2000;181:1808-1812[CrossRef][Medline] [Order article via Infotrieve]. 8. Famularo G, De Simone C, Marcellini S. Apoptosis: mechanisms and relation to AIDS. Med Hypotheses. 1997;48:423-429[CrossRef][Medline] [Order article via Infotrieve]. 9. Cotton MF, Cassella C, Rapaport EL, Tseng PO, Marschner S, Finkel TH. Apoptosis in HIV-1 infection. Behring Inst Mitt.; 1996:220-231. 10. Chavan SJ, Tamma SL, Kaplan M, Gersten M, Pahwa SG. Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol. 1999;93:24-33[CrossRef][Medline] [Order article via Infotrieve]. 11. Aries SP, Weyrich K, Schaaf B, Hansen F, Dennin RH, Dalhoff K. Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1. Scand J Immunol. 1998;48:86-91[CrossRef][Medline] [Order article via Infotrieve]. 12. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 2000;16:559-567[CrossRef][Medline] [Order article via Infotrieve]. 13. Gulnik S, Erickson JW, Xie D. HIV protease: enzyme function and drug resistance. Vitam Horm. 2000;58:213-256[CrossRef][Medline] [Order article via Infotrieve]. 14. Navia MA, McKeever BM. A role for the aspartyl protease from the human immunodeficiency virus type 1 (HIV-1) in the orchestration of virus assembly. Ann N Y Acad Sci. 1990;616:73-85[CrossRef][Medline] [Order article via Infotrieve]. 15. Stennicke HR, Salvesen GS. Catalytic properties of the caspases. Cell Death Differ. 1999;6:1054-1059[CrossRef][Medline] [Order article via Infotrieve]. 16. Popov ME, Kashparov IV, Rumsh LD, Popov EM. Mechanism of action of aspartic proteases, III: conformational characteristics of HIV-1 protease inhibitor JG-365. Bioorg Khim. 1999;25:418-422[Medline] [Order article via Infotrieve].
17.
Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS.
Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.
Blood.
1999;94:1021-1027
18.
Sloand EM, Maciejewski J, Kumar P, Kim S, Chaudhuri A, Young N.
Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells.
Blood.
2000;96:2735-2739 19. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC, Reitz MS Jr. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999;2:261-269[Medline] [Order article via Infotrieve].
20.
Lu W, Andrieu JM.
HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism.
Blood.
2000;96:250-258
21.
Andre P, Groettrup M, Klenerman P, et al.
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
Proc Natl Acad Sci U S A.
1998;95:13120-13124
22.
Schmidtke G, Holzhutter HG, Bogyo M, et al.
How an inhibitor of the HIV-I protease modulates proteasome activity.
J Biol Chem.
1999;274:35734-35740
23.
Ikezoe T, Daar ES, Hisatake JI, Taguchi H, Koeffler HP.
HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.
Blood.
2000;96:3553-3559 24. Lusso P, Cocchi F, Balotta C, et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995;69:3712-3720[Abstract]. 25. McCloskey TW, Chavan S, Lakshmi Tamma SM, Pahwa S. Comparison of seven quantitative assays to assess lymphocyte cell death during HIV infection: measurement of induced apoptosis in anti-Fas-treated Jurkat cells and spontaneous apoptosis in peripheral blood mononuclear cells from children infected with HIV. AIDS Res Hum Retroviruses. 1998;14:1413-1422[Medline] [Order article via Infotrieve].
26.
Bluming AZ, Lynch MJ, Kavanah M, Khiroya R.
Transformation antigens on stimulated lymphocytes.
J Immunol.
1975;114:717-721 27. Rizzardi GP, Pantaleo G. Therapeutic perspectives in HIV-1 infection from recent advances in HIV-1 pathogenesis: it is time to move on. J Biol Regul Homeost Agents. 1999;13:151-157[Medline] [Order article via Infotrieve]. 28. Bright DC. Antiretroviral therapy for HIV infection: a review of current medications and therapies. J Am Optom Assoc. 1999;70:355-383[Medline] [Order article via Infotrieve].
29.
Lempicki RA, Kovacs JA, Baseler MW, et al.
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.
Proc Natl Acad Sci U S A.
2000;97:13778-13783 30. Snasel J, Pichova I. The cleavage of host cell proteins by HIV-1 protease. Folia Biol (Praha). 1996;42:227-230[Medline] [Order article via Infotrieve]. 31. Korant BD, Strack P, Frey MW, Rizzo CJ. A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv Exp Med Biol. 1998;436:27-29[Medline] [Order article via Infotrieve]. 32. Zhang D, Zhang N, Wick MM, Byrn RA. HIV type 1 protease activation of NF-kappa B within T lymphoid cells. AIDS Res Hum Retroviruses. 1995;11:223-230[Medline] [Order article via Infotrieve]. 33. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 1999;20:1499-1508.
34.
Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS.
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression 35. De Paoli P, Zanussi S, Caggiari L, et al. Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. J Clin Immunol. 1999;19:317-325[CrossRef][Medline] [Order article via Infotrieve]. 36. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS. 1997;11:485-491[Medline] [Order article via Infotrieve]. 37. Kornitzer D, Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol. 2000;182:1-11[CrossRef][Medline] [Order article via Infotrieve]. 38. Hershko A. Roles of ubiquitin-mediated proteolysis in cell-cycle control. Curr Opin Cell Biol. 1997;9:788-799[CrossRef][Medline] [Order article via Infotrieve]. 39. Ogasawara H, Takeda-Hirokawa N, Sekigawa I, Hashimoto H, Kaneko Y, Hirose S. Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells. Immunology. 1999;96:215-219[CrossRef][Medline] [Order article via Infotrieve]. 40. Cruikshank WW, Lim K, Theodore AC, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol. 1996;157:5240-5248[Abstract]. 41. Roger PM, Breittmayer JP, Arlotto C, et al. Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients. Clin Exp Immunol. 1999;118:412-416[CrossRef][Medline] [Order article via Infotrieve].
42.
Hazenberg MD, Stuart JW, Otto SA, et al.
T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
Blood.
2000;95:249-255 43. Gougeon ML, Montagnier L. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS: molecular control and effect of highly active anti-retroviral therapy. Ann N Y Acad Sci. 1999;887:199-212[Medline] [Order article via Infotrieve]. 44. Ahsan N, Langhoff E. Immunopathogenesis of human immunodeficiency virus. Semin Nephrol. 1998;18:422-435[Medline] [Order article via Infotrieve].
45.
Peter ME, Ehret A, Berndt C, Krammer PH.
AIDS and the death receptors.
Br Med Bull.
1997;53:604-616
46.
Chirmule N, Pahwa S.
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.
Microbiol Rev.
1996;60:386-406 47. Shostak LD, Ludlow J, Fisk J, et al. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res. 1999;251:156-165[CrossRef][Medline] [Order article via Infotrieve]. 48. McCloskey TW, Ott M, Tribble E, et al. Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol. 1997;158:1014-1019[Abstract].
49.
Zauli G, Gibellini D, Secchiero P, et al.
Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway.
Blood.
1999;93:1000-1010 50. Korant BD, Strack P, Frey MW, Rizzo CJ. A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv Exp Med Biol. 1998;436:27-29.
51.
Renno T, Attinger A, Locatelli S, Bakker T, Vacheron S, MacDonald HR.
Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo.
J Immunol.
1999;162:6312-6315 52. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant. 1996;10:118-123[Medline] [Order article via Infotrieve]. 53. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol. 2000;164:R7-R10[Abstract]. 54. Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med. 1999;246:567-575[CrossRef][Medline] [Order article via Infotrieve]. 55. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection [editorial]. AIDS. 1999;13:2493-2505[CrossRef][Medline] [Order article via Infotrieve]. 56. Mathe G. Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors: prevention by alternating several antiproteases in short sequences [editorial]. Biomed Pharmacother. 1999;53:449-451[CrossRef][Medline] [Order article via Infotrieve].
57.
Gummuluru S, Emerman M.
Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines.
J Virol.
1999;73:5422-5430 58. Dornadula G, Zhang H, Shetty S, Pomerantz RJ. HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission. Virology. 1999;253:10-16[CrossRef][Medline] [Order article via Infotrieve]. 59. Goh WC, Rogel ME, Kinsey CM, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med. 1998;4:65-71[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. Q. Hong-Brown, C. R. Brown, and C. H. Lang Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1482 - C1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Matarrese, L. Gambardella, A. Cassone, S. Vella, R. Cauda, and W. Malorni Mitochondrial Membrane Hyperpolarization Hijacks Activated T Lymphocytes Toward the Apoptotic-Prone Phenotype: Homeostatic Mechanisms of HIV Protease Inhibitors J. Immunol., June 15, 2003; 170(12): 6006 - 6015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Monini, C. Sgadari, G. Barillari, and B. Ensoli HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity J. Antimicrob. Chemother., February 1, 2003; 51(2): 207 - 211. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pati, C. B. Pelser, J. Dufraine, J. L. Bryant, M. S. Reitz Jr, and F. F. Weichold Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma Blood, May 15, 2002; 99(10): 3771 - 3779. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, medium alone; 
, anti-CD3 (0.5 µg/mL); 
, PHA (2 µg/mL);
, PMA (10 ng/mL); + Ionomycin (1 µM); and 
, Con A (2 µg/mL).
) or presence (
), 48 (
), 6 (
, 12.5 µM; 
) followed by assay for caspase activity as described in
the "Materials and methods" section by the release of
7-amino-4-trifluoromethyl coumarin, expressed as relative fluorescence
units (RFU), from caspase-specific fluorogenic substrates over a 2-hour
period. Controls consisted of wells without lysates (
donors,
down-regulatory effect of potent anti-retroviral therapy.
Clin Exp Immunol.
1999;116:115-120